Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02692651 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
A Phase 4 study of Clostridium Difficile Infection (CDI), sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 144
- Enrollment target
- 2
- Study locations
NCT02692651: Completed Phase 4 study of Clostridium Difficile Infection (CDI), sponsored by University of Michigan.
NCT02692651 is a Phase 4 study of Clostridium Difficile Infection (CDI) that has completed, run by University of Michigan. The registered enrollment target is 144 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02692651, a Phase 4 study of Clostridium Difficile Infection (CDI), has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 144 participants
- Enrollment target
- 2
- Study locations
Study Summary
Administration of concomitant antibiotics (CA) is a known risk factor for treatment failure in the treatment of CDI, as well as for recurrence of CDI. Recent data suggested that among patients receiving CA, fidaxomicin is superior to vancomycin. While these data are encouraging, many clinicians remain unclear on how to apply these data to patient care. Additionally, patients were excluded from the trials presented to the FDA if it was expected that they would require ≥ 7 days of CA. Therefore, the clinical question still remains of how to apply these data to the real world patient who requires a long course of CA and develops CDI while on therapy. We therefore propose an open label, comparative and prospective study of fidaxomicin 200 mg twice daily vs oral vancomycin 125 mg four times daily for the treatment of CDI among patients who are receiving a long course of CA. We hypothesize that fidaxomicin will be superior to vancomycin with respect to clinical cure for patients with CDI.
Primary Outcome
Resolution of diarrhea defined as ≤ 3 unformed stools for 2 consecutive days maintained until the end of therapy and for 2 days afterwards. The treatment course was at least 10 days, but it could be extended to a maximum of 12 weeks.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Fidaxomicin
Study Locations (2)
Michigan
- University of Michigan - Ann Arbor
- St. Joseph Mercy Hospital - Ypsilanti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2021-06-23 |
| Phase | Phase 4 |
What the finished NCT02692651 record still lists
NCT02692651 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Clostridium Difficile Infection (CDI) appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT02692651 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02692651 about?
NCT02692651 is a clinical study titled "A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections". Administration of concomitant antibiotics (CA) is a known risk factor for treatment failure in the treatment of CDI, as well as for recurrence of CDI. Recent data suggested that among patients receiving CA, fidaxomicin is superior to vancomycin. While these data are encouraging, many clinicians rema...
What is the current status of trial NCT02692651?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 144 participants. The study started on 2017-05-01. Estimated completion is 2021-06-23.
What conditions does trial NCT02692651 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection (CDI).
What interventions are being tested in trial NCT02692651?
The interventions under investigation include: Vancomycin (DRUG), Fidaxomicin (DRUG).
Who is sponsoring clinical trial NCT02692651?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02692651 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02692651's enrollment target sits among peer trials
144 577th of 2000 higher than 1,422 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI